Medical Educational Programme in Soft Tissue Sarcoma

Copyright

Rick Haas - The Role of Radiotherapy in STS

  • Slide 12 Reproduced with permission from O\'Sullivan B et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma. Presented at ASCO 2004.

  • Slides 14 - 15 Figures 1, 2 and 3 reproduced from Cannon CP et al. Complications of combined modality treatment of primary lower extremity soft tissue sarcomas. Cancer. 2006;107:2455-61.

  • Slide 18 Reproduced from Betgen A, et al. Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT. J Radiat Oncol 2013;2:55-62.

  • Slide 21 Reprinted from Int J Radiat Oncol Biol Phys, 74, DeLaney TF et al., Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas, 732-9., Copyright 2009, with permission from the American Society for Radiation Oncology.

  • Slide 28 Reprinted from Int J Radiat Oncol Biol Phys, 74, DeLaney TF et al., Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas, 732-9., Copyright 2009, with permission from the American Society for Radiation Oncology.

Piotr Rutkowski - Surgery of Soft Tissue Sarcomas

  • Slide 6 Reproduced from Gutierrez et al. Ann Surg 2007;245:925-58, © 2007 with permission of Wolters Kluwer Health

  • Slide 13 Reproduced with kind permission from Springer Science+Business Media: Potter et al. Clin Orthop Related Res 2008;466:3093-100, © 2008; and Qureshi et al. Ann Surg Oncol 2012;19:871-7, © 2012

  • Slide 14 Reproduced from Rutkowski et al. Clin Orthop Relat Res 2013;471:860-70. The article is published under the CC-BY license

  • Slide 15 Gronchi et al. J Clin Oncol 2005;23:96-10. Reprinted with permission. © 2005 American Society of Clinical Oncology. All rights reserved

  • Slide 28 Reproduced from Rutkowski et al. EJSO 2011;37:890-6, © 2011, with permission from Elsevier

  • Slide 34 Reproduced from Billingsley et al. Ann Surg 1999;5:602-12, © 1999 with permission of Wolters Kluwer Health

  • Slide 36 Reproduced from Rutkowski et al. J Surg Oncol 2006;93:304-11, © 2006 Wiley-Liss, Inc; DeMatteo et al. Ann Surg 2007;245:347-52, © 2007 with permission of Wolters Kluwer Health; Gronchi et al. Ann Surg 2007;245:341-6, © 2007 with permission of Wolters Kluwer Health; Raut et al. J Clin Oncol 2006;24:2325-31, © 2006 American Society of Clinical Oncology. All rights reserved

JY Blay Organisation, patient outcome, research

  • Slide 9 Reprinted with permission. © 2009 American Society of Clinical Oncology. All rights reserved. Demetri GD et al: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25), 2009: 4188-96.

  • Slide 10 Reprinted from The Lancet, 379, van der Graaf WTA et al., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, 1879-86, Copyright 2012, with permission from Elsevier.

  • Slide 11 Reprinted from The Lancet, 350, Sarcoma Meta-analysis Collaboration, Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data, 1647-54, Copyright 1997, with permission from Elsevier.

  • Slide 12 Reprinted with permission. © 2001 American Society of Clinical Oncology. All rights reserved. Frustaci S et al: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19(5), 2001: 1238-47. Reprinted from Lancet Oncol, 13, Woll P et al., Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial, 1045-54, Copyright 2012, with permission from Elsevier.

  • Slide 13 Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved. Maki RG et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002 J Clin Oncol 25(19), 2007: 2755-63. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved. Garcia del Muro X et al: Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study J Clin Oncol 29(18), 2011: 2528-33.

  • Slide 14 Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved. Penel N et al: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study J Clin Oncol 26(32),2008: 5269-74. Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved. Kummar S et al: Cediranib for metastatic alveolar soft part sarcoma J Clin Oncol 31(18), 2013: 2296-302.

  • Slide 16 Reprinted with permission. © 2010 American Society of Clinical Oncology. All rights reserved. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients J Clin Oncol 28(7), 2010: 1247-53.

  • Slide 17 Reproduced from Joensuu H et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265-72. Copyright © 2012 American Medical Association. All rights reserved. Reprinted from Lancet Oncol, 13, Joensuu H et al., Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts, 265-74, Copyright 2012, with permission from Elsevier.